Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Belle case study – Nu.Q® Vet Cancer Test

Monday, January 22, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article features Dr. Sue Ettinger discussing Belle's experience with the Nu.Q® Vet Cancer Test. This innovative test is gaining attention in veterinary oncology, and its upcoming publication in a peer-reviewed journal may lead to a $5 million milestone payment for Volition. The test's automation in collaboration with Fujifilm Vet Systems is also noted.
Price reaction · baseline $19.856 (2024-01-19 close) · hit pre-market · 15 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
+0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • The Nu.Q® Vet Cancer Test shows promise in veterinary oncology.
  • Dr. Sue Ettinger highlights a successful case study with Belle.
  • The upcoming publication could unlock a significant financial milestone.

Full Press Release Details

Watch our short video, featuring Dr. Sue Ettinger, aka Dr. Sue Cancer Vet, as she describes Belle’s story with the Nu.Q ® Vet Cancer Test.

Related Articles

• Press Releases Volition Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment
• Press Releases Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

Volition Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment

Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the Nu.Q® Vet Cancer Test?

The Nu.Q® Vet Cancer Test is an innovative diagnostic tool for detecting cancer in pets.

Who is Dr. Sue Ettinger?

Dr. Sue Ettinger, known as Dr. Sue Cancer Vet, is a veterinarian specializing in oncology.

What milestone is associated with the Nu.Q® Vet Cancer Test?

The publication of a related study in a peer-reviewed journal may unlock a $5 million milestone payment.

What collaboration is mentioned in the article?

The article mentions a collaboration with Fujifilm Vet Systems for automating the Nu.Q® Vet Cancer Test.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Nu.Q Vet Cancer Test Dr. Sue Ettinger veterinary oncology Fujifilm Vet Systems
Last updated: Jan 22, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk